-
MMP7–β-Catenin Signaling in Biliary Atresia Fibrosis
2026-09-21
A 2026 study identifies MMP7 as a mechanistic driver of epithelial–mesenchymal transition and liver fibrosis in biliary atresia, linking E-cadherin cleavage to β-catenin nuclear translocation. Its combination of patient samples, transcriptomic analysis, cell experiments, and a chronic mouse model supports MMP7 and the E-cadherin/β-catenin axis as testable antifibrotic targets.
-
Forskolin Workflows for Pancreatic Organoids
2026-09-21
Use Forskolin as a controlled adenylate cyclase activator to test how cAMP modulation affects pancreatic ductal organoid initiation, composition, and stability. This practical guide connects organoid optimization with stem-cell, neuroendocrine, inflammatory, and cardiovascular disease research while separating reference-backed findings from assay starting points.
-
Cy5 Goat Anti-Rabbit IgG (H+L) Antibody Workflow
2026-09-20
Translate rabbit-primary immunoassays into sensitive far-red readouts for MAVS, ASB3, and antiviral signaling studies. This workflow combines practical fluorescence optimization with controls that prevent signal amplification from being mistaken for mechanistic proof.
-
Bufalin Targets STK33 in Triple-Negative Breast Cancer
2026-09-19
A 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct binding partner and degradation target of Bufalin in triple-negative breast cancer. By combining target-discovery assays, mechanistic studies, animal models, and patient-derived organoids, the work connects STK33 loss to reduced tumor growth and provides a framework for evaluating Bufalin as a chemical probe in TNBC research.
-
Dicloxacillin Activity Against Intracellular S. aureus
2026-09-19
The reference study integrated THP-1 macrophage experiments with a murine peritonitis model to compare dicloxacillin activity against extracellular and intracellular Staphylococcus aureus. Its key translational finding was that free-drug time above the MIC, rather than peak concentration or total exposure alone, best predicted efficacy in both compartments.
-
RISOTTO Trial: Risedronate for RA-Associated GIO
2026-09-18
The RISOTTO study was a six-month multicentre, double-blind, randomized, placebo-controlled trial evaluating sodium risedronate in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis. Its principal finding was a significantly greater improvement in lumbar spine bone mineral density with risedronate, with no serious adverse events reported, supporting its role in clinically relevant bone metabolism research.
-
Fritillaria Alkaloids Target MyD88/TRIF Inflammation
2026-09-17
This study identifies four Fritillaria isosteroidal alkaloids that suppress LPS-induced inflammatory responses in macrophages and links their activity to coordinated MyD88-, TRIF-, NF-κB-, and MAPK-related signaling. Ebeiedinone and peimisine also reduced pathological changes in a rat acute lung injury model, supporting further investigation while leaving direct molecular targets and translational efficacy unresolved.
-
Risedronate Sodium: FPPS Workflows for Bone Research
2026-09-17
Build reproducible Risedronate Sodium experiments around FPPS inhibition, osteoclast-mediated bone resorption inhibition, and lung-targeted delivery. This guide connects solution handling, cell assays, dendrimer formulation, in vivo endpoints, and troubleshooting to evidence from a pulmonary osteoporosis study.
-
(-)-Arctigenin Workflow for NF-κB and MEK1 Studies
2026-09-16
Build a controlled workflow around (-)-Arctigenin to interrogate LPS-driven iNOS signaling, MEK1 activity, and macrophage–breast cancer communication. The approach combines pathway-resolved dosing with extracellular-vesicle controls, helping distinguish direct pharmacology from changes in tumor-microenvironment signaling.
-
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide
2026-09-16
The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat-derived IgG primary antibodies in ICC/IF, frozen and paraffin tissue staining, flow cytometry, and ELISA. It should not be treated as a universal secondary reagent: it is intended for goat IgG detection and requires assay-specific validation, controls, and fluorescence-compatible instrumentation.
-
CB-839 (Telaglenastat) Workflow for GLS1 Studies
2026-09-15
Build stronger glutaminolysis inhibition assays with CB-839 (Telaglenastat), from DMSO stock handling through metabolic, viability, and autophagy readouts. This workflow also shows how to translate PRMT5-linked glutamine metabolism findings into practical, hypothesis-driven cancer metabolism research.
-
STING agonist-1: Designing Causal Immune Assays
2026-09-14
STING agonist-1 enables controlled investigation of STING pathway activation in innate immunity. This article translates recent ESCC findings into a practical assay framework for separating proximal signaling, B-cell activation, and tumor-immune organization.
-
KN-62: Reliable CaMKII Assay Workflows
2026-09-14
This scenario-based guide explains how KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine (SKU A8180), can support controlled studies of CaMKII-dependent calcium signaling, secretion, metabolism, and proliferation. It emphasizes solvent controls, orthogonal viability measurements, dose-response interpretation, and practical product-selection criteria for reproducible laboratory workflows.
-
Lactate: From Metabolic Readout to Causal Signal
2026-09-13
Lactate and L-lactate are more than glycolytic endpoints: they connect redox balance, cellular transport, hypoxia, and immune regulation. This article presents a compartment-aware strategy for using lactate measurements to distinguish metabolic correlation from mechanism, including insights from the NAT1–ENO1–lactate axis in colorectal cancer.
-
Risedronate Sodium: FPP Synthase Inhibitor
2026-09-12
Risedronate Sodium is a bisphosphonate and FPP synthase inhibitor that suppresses osteoclast-mediated bone resorption. Evidence supports its use in osteoporosis research, while pulmonary nano-delivery and macrophage-targeted formulations remain preclinical strategies.